Sotrastaurin (AEB071)

For research use only. Not for use in humans.

目录号：S2791

Sotrastaurin (AEB071) Chemical Structure

CAS No. 425637-18-9

Sotrastaurin (AEB071) 是一种有效的，选择性的泛PKC抑制剂，最有效作用于PKCθ，无细胞试验中Ki为0.22 nM；对PKCζ没有活性。Phase 2。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1566.89 现货
RMB 1414.55 现货
RMB 5468.97 现货
有超大折扣
大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户使用Selleck生产的Sotrastaurin (AEB071)发表文献55篇：

产品安全说明书

PKC抑制剂选择性比较

生物活性

产品描述 Sotrastaurin (AEB071) 是一种有效的，选择性的泛PKC抑制剂，最有效作用于PKCθ，无细胞试验中Ki为0.22 nM；对PKCζ没有活性。Phase 2。
特性 同以往的PKC抑制剂不同，AEB071并不会在激活诱导的细胞死亡模型中增强鼠T细胞原幼细胞的凋亡。
靶点
PKCθ [1]
(Cell-free assay)		 PKCβ1 [1]
(Cell-free assay)		 PKCα [1]
(Cell-free assay)		 PKCη [1]
(Cell-free assay)		 PKCδ [1]
(Cell-free assay)
0.22 nM(Ki) 0.64 nM(Ki) 0.95 nM(Ki) 1.8 nM(Ki) 2.1 nM(Ki)
体外研究

在人和鼠的早期T细胞中，毫微摩尔级浓度的AEB071 (< 10μM)则能有效消除早期T细胞激活的信号如白介素-2分泌物和CD25表达。在没发生非特异性抗增殖的效应的细胞中，AEB071 (200 nM)能抑制CD3/CD28抗体和同种抗原诱导的T瞎报增殖反应。AEB071(<3 μM)可以显著抑制淋巴细胞功能相关抗原1介导的T细胞的粘附作用。[1] AEB071(< 20 μM)特异性地降低CD79突变体ABC DLBCL细胞系的增殖，随之能减少NF-κB信号活性。3 μM 浓度的AEB071可诱导CD79突变细胞在G1阻断和/或细胞坏死。[2]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
T cell MoW4SpVv[3Srb36gRZN{[Xl? M{P1VFExOCCwTR?= Mnr6N{Bp MmnySG1UVw>? M1jLW4lvcGmkaYTzJJJTVkFic4nueIhme2m| M4LxWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkmxNVU5Lz5{NU[5NVE2QDxxYU6=
HUVECs  M3XJVmZ2dmO2aX;uJGF{e2G7 MlHROVAxdk1? NVLUeVJqOSCq MYLS[YR2[2W|IFTUXE1VemmpZ3Xy[YQhTW6mb4To[Yxq[WxiRInz[pVv[3Srb36= MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ|NEWzPEc,OjV4M{S1N|g9N2F-
A549 NWT3ZmpWTnWwY4Tpc44hSXO|YYm= Mo\iNE4yyqEQvF2= M{C2cFI1KGh? MUDk[YNz\WG|ZYOgeIhmKHKnbHH0bZZmKFCNQz5OtUBt\X[nbDDvckBk\WyuIH3lcYJz[W6nIHPveJJm[XSnZDDBV{1KXg>? NHvFUI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKxPFE3OSd-MkWyNVgyPjF:L3G+
A549 M2H6T2Z2dmO2aX;uJGF{e2G7 NXPuZ3NCOC5zwrFOwG0> NYLVWnBlOjRiaB?= NVHtWZNJemWmdXPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdHNib3[gUW1RNTJuIF3NVE06KGGwZDDpcpRm\3KrbjFOtlE> NEDZeXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKxPFE3OSd-MkWyNVgyPjF:L3G+
A549 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXtNE4yyqEQvF2= NH3OemszPCCq MXPlcohidmOnczDndo94fGhiaX7obYJqfGmxbjDjc5Rz\WG2ZXSge4l1cCCDUz3JWi=> NUHkSJVoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNVgyPjFpPkK1NlE5OTZzPD;hQi=>
Mel202 M330bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV:wMlUh|ryP NVzkOZNpOyCq MYjEUXNQ M1HOdYVvcGGwY3XzJGlTNWmwZIXj[YQhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6 NITCOVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW5OVM5PSd-MkS1PVU{QDV:L3G+
92.1 M37sbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2G2clAvPSEQvF2= MXmzJIg> NGfBSHdFVVOR MVjlcohidmOnczDJVk1qdmS3Y3XkJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fS=> MkDVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3OUWzPFUoRjJ2NUm1N|g2RC:jPh?=
OCM3 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX:wMlUh|ryP MYWzJIg> NVToNlYxTE2VTx?= NWTtSHlY\W6qYX7j[ZMhUVJvaX7keYNm\CC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHl? MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV7NUO4OUc,OjR3OUWzPFU9N2F-
Mel202 NGnU[HlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzHNE42KM7:TR?= MX[zJIg> MX\EUXNQ M3TqPIlv[3KnYYPld{BKWi2rbnT1Z4VlKGOnbHygZ5lkdGViYYLy[ZN1yqB? NE\odms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW5OVM5PSd-MkS1PVU{QDV:L3G+
92.1 M1L6VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfxNJcxNjVizszN M1q3R|MhcA>? M{HGSGROW09? NXnlOWNOcW6lcnXhd4V{KEmULXnu[JVk\WRiY3XscEBkgWOuZTDhdpJme3UEoB?= MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV7NUO4OUc,OjR3OUWzPFU9N2F-
OCM3 NXL1RotjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVThR3JFOC53IN88US=> MY[zJIg> NIjFeY1FVVOR NYPVZZBGcW6lcnXhd4V{KEmULXnu[JVk\WRiY3XscEBkgWOuZTDhdpJme3UEoB?= M4jReVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUm1N|g2Lz5{NEW5OVM5PTxxYU6=
Jeko-1 M4\nWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2O2W|AuPCEQvF2= MmnPSG1UVw>? MlrJbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NXTtcmdjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOlI6OzVpPkK0N|YzQTN3PD;hQi=>
Mino M2TlbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXq5NplrOC12IN88US=> MX7EUXNQ NGjqPGxqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NUW4Onp2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOlI6OzVpPkK0N|YzQTN3PD;hQi=>
Rec-1 NIKzVmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjKc5MxNTRizszN NEf5UplFVVOR NFz5NopqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN4MkmzOUc,OjR|NkK5N|U9N2F-
SP49 NVe2em1RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGKxW|IxNTRizszN NYDlclNWTE2VTx?= MYTpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 M{[xbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{[yPVM2Lz5{NEO2Nlk{PTxxYU6=
Jeko-1 NX;ve3M{TnWwY4Tpc44hSXO|YYm= MmDDNk42KM7:TdMg Mn7zNVIhcA>? MYfEUXNQ NVvFSWxO\G:5boLl[5Vt[XSnczDOSk3PwkJidHHy[4V1KGenbnXz NIK2WWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO2Nlk{PSd-MkSzOlI6OzV:L3G+
Mino NUnKN|EyTnWwY4Tpc44hSXO|YYm= MlrVNk42KM7:TdMg NH;ES2EyOiCq NXjHbmduTE2VTx?= MnSz[I94dnKnZ4XsZZRmeyCQRj5OvmIhfGG{Z3X0JIdmdmW| M37F[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{[yPVM2Lz5{NEO2Nlk{PTxxYU6=
Rec-1 MYTGeY5kfGmxbjDBd5NigQ>? NYHkXJRJOi53IN88UeKh NGLZO|AyOiCq NIW5c4hFVVOR NEjIUIpld3ewcnXneYxifGW|IF7GMe67SiC2YYLn[ZQh\2WwZYO= NXTJbm5XRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOlI6OzVpPkK0N|YzQTN3PD;hQi=>
SP49 NFjFWlFHfW6ldHnvckBCe3OjeR?= MVuyMlUh|ryPwrC= MmfyNVIhcA>? MoPvSG1UVw>? Mkfu[I94dnKnZ4XsZZRmeyCQRj5OvmIhfGG{Z3X0JIdmdmW| MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN4MkmzOUc,OjR|NkK5N|U9N2F-
CD3+ T  NUfOfY9NTnWwY4Tpc44hSXO|YYm= MVSwMVUxOCCwTR?= NWfad3JsOSCq NHLONJNqdmirYnn0d{BPTi4QulKgdIhwe3Cqb4L5cIF1cW:wIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NISwVZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W3N|I5Oyd-MkO1O|MzQDN:L3G+
Mel202 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfKfYpxOC13IN88US=> NXvxPVJtPzJiaB?= NFfBVXFFVVOR MoTZbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjZ3M{m2PEc,OjJ4NUO5Olg9N2F-
Omm1.3 NF;qWpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnNdpU{OC13IN88US=> MVK3NkBp M2Gy[2ROW09? NX;CZpgzcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjZ3M{m2PEc,OjJ4NUO5Olg9N2F-
92.1 NITtSY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13KU|AuPSEQvF2= NHLLTXA4OiCq Mn3JSG1UVw>? MnrHbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MkLZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4NUO5OlgoRjJ{NkWzPVY5RC:jPh?=
Mel202 M{D4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULIdVdbPSEQvF2= Mon1NlQhcA>? M2[xW2ROW09? M2L2WIlv\HWlZYOgS|Eh[XK{ZYP0xsA> MmL6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4NUO5OlgoRjJ{NkWzPVY5RC:jPh?=
Omm1.3 MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDSTos2KM7:TR?= MXWyOEBp NYHBdGFbTE2VTx?= NXHhU29OcW6mdXPld{BIOSCjcoLld5TDqA>? MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjZ3M{m2PEc,OjJ4NUO5Olg9N2F-
92.1 M{PJeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13SRVUh|ryP MUmyOEBp NF62O2dFVVOR NWPw[4pCcW6mdXPld{BIOSCjcoLld5TDqA>? NVnoNFJmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2OVM6PjhpPkKyOlU{QTZ6PD;hQi=>
Mel202 NV32fYtVSXCxcITvd4l{KEG|c3H5 MnHTOUDPxE1? NHzBfos4OiCq M4O0TmROW09? MojNbY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= NEj0c3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mk[1N|k3QCd-MkK2OVM6Pjh:L3G+
Omm1.3 NXz3fFR7SXCxcITvd4l{KEG|c3H5 MX21JO69VQ>? NYTZb5pjPzJiaB?= NUflN|VUTE2VTx?= M2\YdIlv\HWlZYOgZZBweHSxc3nz MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjZ3M{m2PEc,OjJ4NUO5Olg9N2F-
92.1 NFW2VZNCeG:ydH;zbZMhSXO|YYm= M2HueFUh|ryP MoHyO|IhcA>? NVHVZZQxTE2VTx?= MmTVbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoY3HueIx6 NHT3R2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mk[1N|k3QCd-MkK2OVM6Pjh:L3G+
Mel202 NXrOeWg3TnWwY4Tpc44hSXO|YYm= MX:1JO69VQ>? NX;P[3MxOjRiaB?= M17EWIlvcGmkaYTzJIV5eHKnc4Ppc44h[W6mIIDoc5NxcG:{eXzheIlwdiCxZjDQT2MhcXOxZn;ycZM> MlXmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4NUO5OlgoRjJ{NkWzPVY5RC:jPh?=
Omm1.3 M{niV2Z2dmO2aX;uJGF{e2G7 NH;3bpo2KM7:TR?= M2PieFI1KGh? MkPSbY5pcWKrdIOg[ZhxemW|c3nvckBidmRicHjvd5Bpd3K7bHH0bY9vKG:oIGDLR{Bqe2:ob4Ltdy=> NUDLNVl[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2OVM6PjhpPkKyOlU{QTZ6PD;hQi=>
92.1 MmD0SpVv[3Srb36gRZN{[Xl? NXjPOoFKPSEQvF2= MW[yOEBp MWPpcohq[mm2czDlfJBz\XO|aX;uJIFv\CCyaH;zdIhwenmuYYTpc44hd2ZiUFvDJIl{d2[xcn3z NXP1R5ZnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2OVM6PjhpPkKyOlU{QTZ6PD;hQi=>
HBL1 NYnJTnM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGm4So8xNjF4LUKwJO69VQ>? NF3hW4I2KGR? M2P6fmlEPTB;MD61JO69VQ>? MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN{NEmyNEc,OjF|MkS5NlA9N2F-
TMD8 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HxdlAvOTZvMkCg{txO MYe1JIQ> NULJN2Q6UUN3ME2wMlIh|ryP MlTLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|MkS5NlAoRjJzM{K0PVIxRC:jPh?=
OCI-Ly10 NHmxOolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHNNE4yPi1{MDFOwG0> NXHIV4szPSCm MYDJR|UxRTFwMzFOwG0> NV24VFh2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzNlQ6OjBpPkKxN|I1QTJyPD;hQi=>
U2932 MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PxW|AvOTZvMkCg{txO Mly2OUBl NHfJboNKSzVyPUGwJO69VQ>? NFnROpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUOyOFkzOCd-MkGzNlQ6OjB:L3G+
OCI-Ly3 M4DyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUSwMlE3NTJyIN88US=> MYi1JIQ> MWXJR|Ux97zgMkCg{txO NVyzWZFpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzNlQ6OjBpPkKxN|I1QTJyPD;hQi=>
SuDHL2 NHPXTJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXwNE4yPi1{MDFOwG0> NWrhWoZZPSCm NX3aSFlQUUN3MP-8olIxKM7:TR?= NVi3e4FwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzNlQ6OjBpPkKxN|I1QTJyPD;hQi=>
SuDHL4 MoPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTJNE4yPi1{MDFOwG0> NFnxUHI2KGR? NH7jdoFKSzVy78{eNlAh|ryP M4HlcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{K0PVIxLz5{MUOyOFkzODxxYU6=
DB MofwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXO2fFN{OC5zNj2yNEDPxE1? NXntPJpvPSCm NF:2dYlKSzVy78{eNlAh|ryP MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN{NEmyNEc,OjF|MkS5NlA9N2F-
Jurkat IL-2 NED5eHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XSTWlEPTB;Nj63NUDDuSB|Lke2JO69VQ>? M2OxbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUSwNlU6Lz5zOUm0NFI2QTxxYU6=
PBMC IL-2 Mo\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3njXmlEPTB;ND64OEDDuSBzLkewJEDPxE1? M{LjdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUSwNlU6Lz5zOUm0NFI2QTxxYU6=
Jurkat NYjIVotuTnWwY4Tpc44h[XO|YYm= MX;Jcohq[mm2aX;uJI9nKFSFUj;DSFI5NW2nZHnheIVlKGi3bXHuJHQh[2WubDDhZ5RqfmG2aX;uJIlvKEq3cnvheEBk\WyuczDlfJBz\XO|aX7nJIh2dWGwIFnMNkBxem:vb4TldkBjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmsJGlEPTBiPTCwMlA2PCEQvF2u MmDuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6Mke4N|EoRjF7OEK3PFMyRC:jPh?=
Jurkat T MULGeY5kfGmxbjDhd5NigQ>? Mo\ZOUBpenN? MkL6TY5pcWKrdHnvckBw\iCSS1P0bIV1[SCrbjDoeY1idiCMdYLrZZQhXCClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZY51cS2FREOvR2QzQCCjboTpZo9lgS2rbnT1Z4VlKFRvY3XscEBi[3SrdnH0bY9vKGK7IH3lZZN2emmwZzDk[YNz\WG|ZTDpckBKVC1{IIPlZ5JmfGmxbjDh[pRmeiB3IHjyd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmsJGlEPTBiPTCwMlA5OSEQvF2u MonhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhzM{G3NVQoRjJ6MUOxO|E1RC:jPh?=
B-cells MVrGeY5kfGmxbjDhd5NigQ>? MU\Jcohq[mm2aX;uJI9nKFCNQ3LleIEhcW5ibX;1d4UhSiClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gTYdONXO2aX31cIF1\WRiY3XscEBxem:uaX\ldoF1cW:wLDDJR|UxKD1iMD6yN|Qh|ryPLh?= NILUfpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEGzNVcyPCd-MkixN|E4OTR:L3G+
bone marrow cells NULiOGF3SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NHr5RZg1KGSjeYO= NGLocJFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGNDSSCvb4Xz[UBjd26nIH3hdpJwfyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHs{UF22aIntbYRqdmViaX7jc5Jxd3KjdHnvckBi\nSncjC0JIRigXNuIFnDOVAhRSB|Lkeg{txONg>? NHWxWW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUiyO|g{OSd-MUm4Nlc5OzF:L3G+

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
pPKCδ/θ / phosphorylated MARCKS / p53 / MDM2 / PUMA / p21; 

PubMed: 29593251     


Cell lines OMM2.3, OMM2.5 and OMM1 were treated with 8 µM Nutlin-3 and 4 µM Sotrastaurin. MEL290 was incubated with 2 µM Nutlin-3 and 4 µM Sotrastaurin, cell line MM28 with 8 µM Nutlin-3 and 1 µM Sotrastaurin, and cell lines MEL202, MEL270 and MM66 with 2䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ뙠ෆ䐺痖暼瘿뙠ෆᾰƌ 뙠ෆÐ㺣痖뙠ෆ€𢡄뙤ෆ€䀷痗뙤ෆ౴뙤ෆ㵶痗뙤ෆ뺖᎒泌Itemｾ᎒Count﫨呂뚔ෆ猴፲뙤ෆ፲씢痗猸፲髸莤䥷堙᎒ｾ᎒�堞ﻮ᎒፲露𢡄堚Ѽ齃礤v�堞ﻮ᎒猢Wｾ᎒䨼Ą鹿齃

Cyclin D1 / p27(Kip1) ; 

PubMed: 22653968     


AEB071 selectively increased p27 and decreased cyclin D1 expression in GNAQ mutant UM cells. Cells were treated with 0, 2, or 5 μM AEB071 for 72 hours and analyzed by immunoblot. WT = GNAQ wild type; MT = GNAQ mutation.

Bcl-xl / XIAP / Survivin ; 

PubMed: 22653968     


AEB071 decreased the expression of antiapoptotic proteins Bcl-xL, XIAP, and survivin in GNAQ mutated cells. WT = GNAQ wild type; MT = GNAQ mutation.

PKCα / PKCδ / PKCβ / PKCε / PKCθ ; 

PubMed: 22653968     


AEB071 inhibited PKC expression in UM cells. Cells were treated with 5 μM AEB071 for 24 hours in the presence of 10% FBS and subjected to immunoblot analysis. PKCδ, ε and θ levels in AEB treated cells relative to control (DMSO treated) cells are also show䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෕Ð鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ삨Ղ䐺痖暼瘿삨Ղᾰƌ 삨Ղà㺣痖삨Ղ€𢡄사Ղ€䀷痗사Ղ౴사Ղ㵶痗사Ղ뺖᎒泌Itemｾ᎒Count﫨呂샜Ղ猴፲사Ղ፲씢痗猸፲髸莤䥷堙᎒

p-Marcks / p-ERK / p-AKT / p-S6 / Marcks / ERK / AKT / S6; 

PubMed: 22653968     


AEB071 inhibits PKC and mTOR pathways but not AKT. Western Blot of MARCKS, ERK, ribosomal S6 and AKT phosphorylation following drug treatments for 24 hrs. α-Tubulin was used as a loading control.

29593251 22653968
Growth inhibition assay
Cell viability ; 

PubMed: 22653968     


AEB071 selectively reduced viability of UM cells harboring GNAQ mutations. Cells were treated with varying amount of AEB071 for 72 hours. Data are presented as mean±SD of 4 or 5 independent experiments. NM = normal melanocytes; WT = GNAQ wild type; MT = G䲧疝Ỵ疞㧀疜膉

22653968
体内研究 AEB071(80 mg/kg) 可以在体内显著抑制SCID的皮下TMD8移植模型肿瘤的生长。[2] 每日两次口服10 mg/kg 和30 mg/kg AEB071，能延长心脏移植的大鼠的存活率，这种作用是剂量依赖抑制免疫力的效应。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

动物实验：[3]
- 合并
  • Animal Models: 雄性 Wistar/F大鼠
  • Dosages: 10 mg/kg 和 30 mg/kg
  • Administration: 口服一次
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 87 mg/mL (198.41 mM)
Water Insoluble
Ethanol '2 mg/mL
体内 从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)：
2% DMSO+30% PEG 300+ddH2O
 10mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 438.48
化学式

C25H22N6O2
CAS号 425637-18-9
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量 只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02273219 Unknown status Drug: AEB071|Drug: BYL719 Uveal Melanoma Richard D. Carvajal|Columbia University November 2014 Phase 1
NCT01801358 Terminated Drug: AEB071|Drug: MEK162 Uveal Melanoma Array Biopharma now a wholly owned subsidiary of Pfizer|Array BioPharma August 2013 Phase 1|Phase 2
NCT01430416 Completed Drug: AEB071 Uveal Melanoma Novartis Pharmaceuticals|Novartis December 20 2011 Phase 1
NCT01402440 Terminated Drug: AEB071 Diffuse Large B-Cell Lymphoma Novartis Pharmaceuticals|Novartis November 2011 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1：

    Could you give me the information about how to prepare Sotrastaurin for oral administration in mice?

  • 回答：

    S2791 Sotrastaurin can be dissolved in 2% DMSO/30% PEG 300/ddH2O at 10 mg/ml as a clear solution which can be used for injection, and in 2% DMSO/corn oil at 10 mg/ml as a suspension for oral administration.

Selleck产品目录册

PKC Signaling Pathway Map

PKC Inhibitors with Unique Features

  • 选择性强的PKC抑制剂

    Enzastaurin (LY317615) : PKCβ-selective, IC50=6 nM.

  • 活性最高的PKC抑制剂

    Go 6983 : PKCα, IC50=7 nM; PKCβ, IC50=7 nM; PKCγ, IC50=6 nM; PKCδ, IC50=10 nM.

  • 用于临床的PKC抑制剂

    Dequalinium Chloride : Phase III for Bacterial Vaginosis.

相关PKC产品

  • SD-208 New

    SD-208是一种选择性TGF-βRI (ALK5)抑制剂，with IC50为48 nM，选择性比TGF-βRII高100多倍。

  • Staurosporine (AM-2282)

    Staurosporine (AM-2282, Antibiotic AM-2282, STS)是一种有效的PKC抑制剂，在无细胞试验中作用于PKCα，PKCγ 和PKCη，IC50分别为2 nM，5 nM 和 4 nM，对PKCδ(20 nM)和PKCε(73 nM作用较弱，对PKCζ (1086 nM)的活性很低。同时 对其他的激酶PKA, PKG, S6K, CaMKII, 等也显示抑制活性。Phase 3。

  • Go 6983

    Go 6983 (GOE 6983, Gö 6983)是一种pan-PKC抑制剂，作用于PKCα， PKCβ， PKCγ和PKCδ，IC50分别为7 nM， 7 nM， 6 nM和10 nM，对PKCζ作用稍弱，抑制PKCμ活性。

  • Enzastaurin (LY317615)

    Enzastaurin (LY317615)是一种有效的PKCβ选择性抑制剂，无细胞试验中IC50为6 nM，比作用于PKCα，PKCγ和PKCε选择性高6到20倍。Phase 3。

  • Bisindolylmaleimide I (GF109203X)

    Bisindolylmaleimide I (GF109203X, GO 6850)是一种有效的PKC抑制剂，作用于PKCα，PKCβI，PKCβII和PKCγ，无细胞试验中IC50分别为20 nM， 17 nM， 16nM和20 nM，作用于PKC比作用于EGFR，PDGFR和胰岛素受体选择性高3000倍以上。

  • Go6976

    Go6976 (PD406976)是一种强效的PKC抑制剂，其对PKC (老鼠大脑), PKCα, and PKCβ1的IC50分别为7.9nM，2.3 nM, 和 6.2 nM 。此外，也是JAK2 和 Flt3的强抑制剂。

  • Dequalinium Chloride

    Dequalinium Chloride是一种PKC抑制剂，IC50为7-18 μM，同时也是一种选择性蜂毒明肽敏感型钾离子通道阻断剂，IC50为1.1 μM.

Tags: 购买Sotrastaurin (AEB071) | Sotrastaurin (AEB071)供应商 | 采购Sotrastaurin (AEB071) | Sotrastaurin (AEB071)价格 | Sotrastaurin (AEB071)生产 | 订购Sotrastaurin (AEB071) | Sotrastaurin (AEB071)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID